Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies

Trial Profile

Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Anakinra (Primary) ; Tocilizumab (Primary) ; Adalimumab
  • Indications Uveitis
  • Focus Therapeutic Use
  • Acronyms RUBI
  • Most Recent Events

    • 04 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 09 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
    • 13 Apr 2017 Planned initiation date changed from 1 Oct 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top